BBNX earnings analysis
What we found in BBNX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Beta Bionics reported Q1 net sales of $27,626 (in thousands) versus $17,639 in Q1 2025, with gross profit of $16,437 and net loss of $(21,895). Gross margin expanded to 59.5% and EPS improved to $(0.49) but the company remains loss-making and used cash in operations. Liquidity remains sizable with cash, short-term and long-term investments of $239,385 (in thousands) but operating cash burn increased vs. prior year.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Strong top-line growth
- Net sales increased to $27,626 (in thousands) in Q1 2026 from $17,639 (in thousands) in Q1 2025, an increase of $9,987 (in thousands) (≈56.6%).
- Gross margin expansion
- Gross profit rose to $16,437 (in thousands) giving a gross margin of 59.5% (16,437/27,626), up from 50.9% in Q1 2025 (8,971/17,639).
- Operating leverage vs. prior year (partial)
- Loss from operations narrowed to $(24,271) (in thousands) from $(18,642) (in thousands) on a higher revenue base, and net loss improved to $(21,895) (in thousands) from $(28,656) (in thousands) year-over-year.
- Liquidity: large cash + investments balance
- Cash and cash equivalents $30,206, short-term investments $169,314 and long-term investments $39,865 (all in thousands), totaling $239,385 (in thousands) available on the balance sheet as of March 31, 2026.
- Company operates as a single segment
- Per Note on segment information, Beta Bionics reports one operating segment — total company net sales $27,626 (in thousands) for the quarter; top customer concentrations include Distributor G 17.8% and Distributor H 17.3% of net sales for the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued operating losses and accumulated deficit
- Company reported a net loss of $(21,895) (in thousands) for the quarter and an accumulated deficit of $(391,832) (in thousands) as of March 31, 2026.
- Negative operating cash flow / free cash flow
- Net cash used in operating activities was $(23,832) (in thousands) in Q1 2026 (worse vs. $(19,975) in Q1 2025) and free cash flow (operating cash flow less capex) was approximately $(25,209) (in thousands) (23,832 + 1,377).
- Working capital compression vs. prior quarter
- Current assets decreased to $247,986 (in thousands) from $267,905 (in thousands) and current liabilities decreased to $23,191 (in thousands) from $30,924 (in thousands), leaving working capital of $224,795 (in thousands) (down $12,186 from $236,981 at 12/31/25).
- Inventory build ties cash
- Inventories increased to $23,727 (in thousands) from $21,722 (in thousands), a $2,005 (in thousands) increase that ties up working capital.
- Decline in short-term investments
- Short-term investments declined to $169,314 (in thousands) from $187,549 (in thousands) at 12/31/25, a reduction of $18,235 (in thousands).
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.49
- Gross margin
- 59.5%
- Operating margin
- -87.9%
- Segment
- One operating segment (total company) — Net sales $27,626 (in thousands) for the three months ended March 31, 2026; top customer concentrations: Distributor G 17.8% and Distributor H 17.3% of net sales.
What they said about what is next.
This 10-Q does not present numeric forward-looking guidance. (Separately, the company disclosed in an 8-K filed 2026-04-21 that it raised full-year 2026 revenue guidance to approximately $131 million–$136 million and raised gross margin guidance to 57.5%–59.5% and PBP new-patient starts guidance to 37%–39%.)
The filing reads about the same as the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BBNX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever